Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom by Lim, Samuel Hsiang, Gros, Beatriz, Sharma, Esha, Lehmann, Anouk, Lindsay, James O, Caulfield, Louise, Gaya, Daniel R, Taylor, Jo, Limdi, Jimmy, Kwok, Jon, Shuttleworth, Elinor, Dhar, Anjan, Burdge, Gemma, Selinger, Christian, Cococcia, Sara, Murray, Charles, Balendran, Karthiha, Raine, Tim, George, Becky, Walker, Gareth, Aldridge, Robin, Irving, Peter, Lees, Charlie W, Samaan, Mark

Get full text

Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab by Miller, Charles, Kwok, Hanson, Harrow, Paul, Vega, Roser, Seward, Edward, Mehta, Shameer, Rahman, Farooq, McCartney, Sara, Parisi, Ioanna, Lim, Samuel Hsiang, Sharma, Esha, Samaan, Mark A, Bancil, Aaron, Kok, Klaartje Bel, Shalabi, Ahmed, Johnston, Emma L, Katarey, Dev, Taherzadeh, Nina, Murray, Charles, Sharip, Mohammed Tauseef, Carter, Martyn J, Radhakrishnan, Shiva T, Peake, Simon, Khakoo, Imran, Wahed, Mahmood, Povlsen, Sebastian, Patel, Mehul, DuBois, Patrick, Finkel, Jemima, Onnie, Clive, Bloom, Stuart

Get full text